HURA Latest Press Releases

-- October 26, 2026 --

TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma PRNewswire 7:31 AM

-- October 13, 2026 --

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 PRNewswire 7:45 AM

-- October 5, 2026 --

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology PRNewswire 7:46 AM

-- September 14, 2026 --

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers PRNewswire 7:45 AM

-- September 8, 2026 --

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 7:46 AM

-- August 14, 2026 --

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PRNewswire 7:45 AM

-- July 22, 2026 --

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference PRNewswire 7:40 AM

-- June 15, 2026 --

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers PRNewswire 7:50 AM

Market Data Delayed 15 Minutes